CARA - Cara Therapeutics, Inc.
After hours:
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.4400 |
| Open | 3.4200 |
| Bid | 3.0400 x 1400 |
| Ask | 3.2900 x 1300 |
| Day's Range | 3.1700 - 3.4500 |
| 52 Week Range | 3.1700 - 12.9800 |
| Volume | |
| Avg. Volume | 765,888 |
| Market Cap | 171.667M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6400 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.86 |
Fair Value
Related Research
Simply Wall St.Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA ) is a stock to...
InvestorPlaceHero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich… or Broke.
While the traditional approach to market success calls for patiently investing in reliable blue chips, those that want to see more immediate gains may consider small-cap stocks to buy. Here, the point is about accepting massive risk to hopefully realize massive rewards. At the same time, these lower-volume enterprises can be volatile, making this category inappropriate for the faint of heart. On the optimistic side of the equation, few other investment categories offer the upside reward potentia
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
- Thomson Reuters StreetEvents
Q1 2023 Cara Therapeutics Inc Earnings Call
Q1 2023 Cara Therapeutics Inc Earnings Call
ZacksCara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 7.55% and 22.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCara Therapeutics Reports First Quarter 2023 Financial Results
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than doubling quarter to quarter – – Three late-stage oral difelikefalin clinical programs progressing with internal readout of Part A of KIND 1 AD trial on track for 4Q23 – – Conference call today at 4:30 p.m. EDT – STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Ca
- Simply Wall St.
Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 65%
Key Insights Institutions' substantial holdings in Cara Therapeutics implies that they have significant influence over...
- GlobeNewswire
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants wi
- GlobeNewswire
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT. A webcast of the presentation can be accessed under "Event
- Simply Wall St.
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility. “Our first ESG repo
- Simply Wall St.
Things Look Grim For Cara Therapeutics, Inc. (NASDAQ:CARA) After Today's Downgrade
The analysts covering Cara Therapeutics, Inc. ( NASDAQ:CARA ) delivered a dose of negativity to shareholders today, by...
Insider MonkeyCara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Good afternoon. My name is Josh, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Update Conference Call. I would now like to introduce Matt […]
MarketWatchMeta’s stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market
ADial Pharmaceuticals stock soars after alcohol disorder treatment clinical trial news, Squarespace rises after estimate-beating results.
- Thomson Reuters StreetEvents
Q4 2022 Cara Therapeutics Inc Earnings Call
Q4 2022 Cara Therapeutics Inc Earnings Call
Yahoo Finance VideoCara Therapeutics stock sinks on larger-than-expected Q4 earnings miss
Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.
Motley FoolThese 2 Stocks Are Plunging After Hours Monday
The stock market was mixed to start the week on Monday, as investors seemed more comfortable waiting to find out what Federal Reserve chair Jerome Powell will say later in the week about the state of the U.S. economy and the central bank's approach to interest rates. The Dow Jones Industrial Average (DJINDICES: ^DJI) and S&P 500 (SNPINDEX: ^GSPC) managed to gain ground on the day, but the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell back slightly. Calavo Growers (NASDAQ: CVGW) is well known for its avocado production, and its quarterly financial results weren't good enough to keep investors satisfied.
ZacksCara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative revenue of $16.6 million – – Positive momentum across first four EU launches; Global rollout to accelerate with most EU countries launching in 2023 – – Phase 2/3 clinical program of oral difelikefalin in NP initiated in 2023; NDD CKD and AD programs tracking to expectations with inter
- Zacks
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update. To participate in the conference call, please register he
- Simply Wall St.
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Cut Their EPS Forecasts Substantially
Market forces rained on the parade of Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders today, when the analysts...
- GlobeNewswire
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatmentSTAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the New England Journal of Medicine (NEJM) has published results from the KOMFORT Phase 2 clinical trial of oral difelikefalin in pa
GlobeNewswireCara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST. The event will highlight the launch of KORSUVA® (difelikefalin) injection and feature presentations during